Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
SAN DIEGO and TORONTO, Aug. 03, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the Canaccord Genuity 37th Annual Growth Conference on Thursday, August 10th, 2017 at 11:30 a.m. ET at the Intercontinental Hotel, Boston, MA.
Dr. Rice will provide a corporate overview of the Company’s recent activities and strategic direction.
| Time: | 11:30 a.m. ET | ||||
| Date: | Thursday, August 10, 2017 | ||||
| Location: | Intercontinental Hotel, Boston, MA | ||||
A live webcast of the Aptose presentation will be accessible by visiting:
http://wsw.com/webcast/canaccord26/apto
The webcast will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Greg Chow, CFO 647-479-9828 [email protected] SMP Communications Susan Pietropaolo 201-923-2049 [email protected]
